Urinary calcium oxalate crystallization

Urinary calcium oxalate crystallization describes the physicochemical process leading to the formation of calcium oxalate crystals in urine, an initial step in kidney stone formation. The process begins when urine becomes supersaturated with calcium and oxalate ions, leading to nucleation, growth, and aggregation of calcium oxalate monohydrate (COM) and dihydrate (COD) crystals[1][2][3][4]. Biological modulators such as urinary proteins (e.g., osteopontin), citrate, and certain polyphosphates can profoundly influence the rate, size, and morphology of these crystals, serving as natural inhibitors and potential therapeutic agents[2][4]. Disruption of this regulation—by metabolic, dietary, or genetic factors—can promote crystal retention in renal tubules, crystal adhesion to epithelial cells, and ultimately stone development[3][6]. No single molecular entity called "urinary calcium oxalate crystallization" exists; it is a process governed by multiple physicochemical and molecular factors, and the relevant 'targets' for drug development are typically the modulators or steps within this pathway rather than the crystallization event itself.

Other names

Calcium oxalate crystallizationCalcium oxalate stone formationCalcium oxalate precipitation

Inhibition of nucleation, growth, and aggregation of calcium oxalate crystals by complexing calcium ions or interfering with crystal surfaces (e.g., citrate, polyphosphates, osteopontin). Altering crystal morphology to reduce adhesiveness and pathogenicity (e.g., shifting from calcium oxalate monohydrate to dihydrate forms).